Source link : https://newshealth.biz/health-news/semaglutide-lowers-sga-related-cardiometabolic-risk/
Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk in individuals with schizophrenia spectrum disorders compared with placebo. Medscape Medical News Source link : https://www.medscape.com/viewarticle/semaglutide-lowers-antipsychotic-related-cardiometabolic-2025a1000yxa?src=rss Author : Publish date : 2025-12-12 13:00:00 Copyright for syndicated content belongs to the linked Source.
The post Semaglutide Lowers SGA-Related Cardiometabolic Risk first appeared on News Health.
—-
Author : News Health
Publish date : 2025-12-12 13:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8